LAG3 and metastatic melanoma: More importantly, a recent study assessing the therapeutic implication of ipilimumab, a CTLA-4 antibody, showed that ipilimumab increased the frequency of LAG-3 expression on tumor-infiltrating cells in metastatic melanoma patients [98].